GlassScriptPhysician profile
David J Grew
NPI 1316265069
$68,088.69
in general payments reported to CMS, 2019-2025
13 companies · $33K in 2025
The $33K reported for 2025 was more than what 99% of Therapeutic Radiology providers received nationally (typical 2025 total: $179).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $22.92 · 2023: $9,199 · 2024: $26K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $67K · Food and Beverage: $766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $67,300.00 |
| Food and Beverage | $765.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $58,322.64 | 2024-2025 | Orgovyx |
| Boston Scientific Corporation | $9,036.15 | 2023-2025 | Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial), Spaceoar System |
| Siemens Medical Solutions USA, INC. | $161.54 | 2023 | Truebeam |
| Blue Earth Diagnostics | $146.38 | 2024-2025 | Posluma |
| Genmab U.S., INC. | $127.35 | 2024 | Tivdak |
| Teleflex LLC | $112.47 | 2024 | |
| Bioprotect Medical, INC. | $37.35 | 2024 | Bioprotect Balloon Implant System |
| Accuray Incorporated | $33.38 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $30.21 | 2025 | Tagrisso |
| Novartis Pharmaceuticals Corporation | $24.21 | 2023 | Pluvicto |
| Myovant Sciences Gmbh | $22.92 | 2022 | |
| Novocure INC. | $21.18 | 2025 | Optune Lua (Novottf-200t) |
| Adaptive Biotechnologies Corporation | $12.91 | 2023 | Clonoseq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Grew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.